RT @UEMSHealthStats: Joint modeling to evaluate the association between benefits and risks of drug therapy in type 2 diabetes https://t.co/…
RT @john_den_: Our new study: Joint longitudinal-survival modeling to evaluate the benefits & risks of drug therapy in #Type2diabetes publi…
Joint modeling to evaluate the association between benefits and risks of drug therapy in type 2 diabetes https://t.co/S2SF7QfH31 #healthstats #healthstatistics #Exeterdiabetes @ExeterMed @UofE_Research @bshieldsexeter @john_den_
RT @john_den_: Our new study: Joint longitudinal-survival modeling to evaluate the benefits & risks of drug therapy in #Type2diabetes publi…
RT @john_den_: Our new study: Joint longitudinal-survival modeling to evaluate the benefits & risks of drug therapy in #Type2diabetes publi…
RT @john_den_: Our new study: Joint longitudinal-survival modeling to evaluate the benefits & risks of drug therapy in #Type2diabetes publi…
Our new study: Joint longitudinal-survival modeling to evaluate the benefits & risks of drug therapy in #Type2diabetes published today in Clinical Epidemiology. Open access https://t.co/YLSO7yYIIB #Exeterdiabetes @ExeterMed @athattersley @bshieldsexe